Marie Beylot-Barry, MD, PhD

A planned mogamulizumab break emerged as best suited to older patients not bound for transplant, pending prospective confirmation.

Stopping mogamulizumab after a strong response — then resuming it at relapse — emerged as a viable strategy for select patients with Sézary syndrome.